欢迎访问《现代生物医学进展》编辑部！

目的：观察缬沙坦联合培哚普利对慢性心力衰竭（CHF）的治疗效果，以及对患者心功能、血浆脑利钠肽（BNP）、C 反应蛋白（CRP）和IL-6 的影响。方法：95 例CHF 患者随机分为缬沙坦治疗组（30 例）、培哚普利治疗组（30 例）和联合治疗组（35 例），患者均予以常规西医治疗，缬沙坦治疗组或培哚普利治疗组在常规治疗基础上加用缬沙坦或培哚普利，联合治疗组则同时加用缬沙坦和培哚普利。观察治疗效果及患者心功能变化，检测治疗前后血浆BNP、CRP、IL-6 的浓度。结果：联合治疗组总有效率达到 91.43%，高于缬沙坦治疗组73.33%和培哚普利53.33%的总有效率(P< 0.05)；与缬沙坦治疗组和培哚普利治疗组相比，缬沙坦联合培哚普利可有效改善患者心功能指标，降低血浆BNP、CRP、IL-6 含量。结论：缬沙坦联合培哚普利能有效改善心功能，调节细胞因子表达，优于单用缬沙坦或培哚普利治疗。

英文摘要:

Objective: To explore the therapeutic effect of combination of valsartan and perindopril in patients with CHF, as well as ventricular function and plasma BNP, IL-6 and CRP. Methods: 95 cases with CHF were randomly divided in to valsartan-treated group (30 cases), perindopril-treated group (30 cases) and combined treatment group (35 cases). The valsartan or perindopril was added to valsartan- treated group or perindopril-treated group on the basis of Western medicine, and valsartan combined with perindopril in combined treatment group. The therapeutic effect, ventricular function and plasma BNP, IL-6 and CRP were evaluated before and after treatment. Results: In the combined treatment group, the total effective rate was 91.43%, significantly higher than 73.33% in valsartan-treated group and 53.33% in perindopril-treated group (P<0.05). Compared with the other two groups, valsartan combined with perindopril effectively improved ventricular function and reduced the levels of BNP, IL-6 and CRP. Conclusion: The combination of valsartan and perindopril could improve ventricular function, regulated expression of cytokines, which is superior to valsartan or perindopril alone in treating patients with CHF.

查看全文查看/发表评论下载PDF阅读器

关闭